VYNE Therapeutics (VYNE) Share-based Compensation (2017 - 2026)
VYNE Therapeutics (VYNE) posted Share-based Compensation of $474000.0 for Q1 2026, up 163.2% on a QoQ basis from -$750000.0 in Q2 2025, and down 37.88% year-over-year from $763000.0 in Q1 2025.
VYNE Therapeutics (VYNE) Share-based Compensation (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Share-based Compensation history runs 10 years deep, the most recent figure standing at $474000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 37.88% year-over-year to $474000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 61.51% YoY) and the FY2025 annual result came in at $16000.0, down 99.52% from the prior year.
- Share-based Compensation was $474000.0 for Q1 2026 at VYNE Therapeutics, up from -$750000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.2 million in Q3 2022 and bottomed at -$3.2 million in Q4 2022.
- A 5-year average of $266466.7 and a median of $734000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 2253.33% — and 2024, when it surged 292.7%.
- VYNE Therapeutics' Share-based Compensation stood at -$3.2 million in 2022, then jumped by 105.51% to $178000.0 in 2023, then jumped by 292.7% to $699000.0 in 2024, then slumped by 207.3% to -$750000.0 in 2025, then soared by 163.2% to $474000.0 in 2026.
- Business Quant data shows VYNE's Share-based Compensation at $474000.0 in Q1 2026, -$750000.0 in Q2 2025, and $763000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 87.30 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 474,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 474,000.00 |
| Mar 31, 2026 | 474,000.00 |
| Jun 30, 2025 | -750,000.00 |
| Jun 30, 2025 | -750,000.00 |
| Mar 31, 2025 | 763,000.00 |
| Mar 31, 2025 | 763,000.00 |
| Dec 31, 2024 | 699,000.00 |
| Dec 31, 2024 | 699,000.00 |
| Sep 30, 2024 | 734,000.00 |
| Sep 30, 2024 | 734,000.00 |
| Jun 30, 2024 | 885,000.00 |
| Jun 30, 2024 | 885,000.00 |
| Mar 31, 2024 | 985,000.00 |
| Mar 31, 2024 | 985,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Sep 30, 2023 | -1.70 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Jun 30, 2023 | 876,000.00 |
| Jun 30, 2023 | 876,000.00 |